Current inhibitors of IL-17A, including anti-IL-17A monoclonal antibodies seckinumab, ixekizumab, and bimekizumab, have been approved for the treatment of autoimmune diseases such as psoriatic arthritis (25) and ankylosing spondylitis (26). Here, IL17A is linked to ankylosing spondylitis.